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Effects of weekly iron and folic acid supplements on malaria risk in nulliparous women in 
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Summary: Weekly iron supplementation, given to young nulliparous women living in a malaria endemic area, 
neither improved iron status nor increased malaria risk, suggesting current iron recommendations may need re-
visiting for these women. 
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Abstract  
Background: Safety of iron supplementation for young women is uncertain in malaria endemic 
settings.  
Methods: Double-blind randomized controlled non-inferiority trial in rural Burkina Faso. 
Results: 1959 nulliparae assigned to weekly supplementation (60 mg iron and 2.8 mg folic acid) 
(n=980) or 2.8 mg folic acid (n=979) until first antenatal visit (ANC1), or 18 months if remaining 
non-pregnant. 315 women attended ANC1, and 916 remained non-pregnant. There was no 
difference at ANC1 in parasitemia prevalence (iron 53.4%, 95% CI 45.7:61.0; control 55.3%, 95% 
CI 47.3:62.9; prevalence ratio 0.97, 95% CI 0.79:1.18; P=0.82); anemia (adjusted effect 0.96, 95% 
CI 0.83:1.10; P=0.52); iron deficiency (adjusted risk ratio 0.84, 95% CI 0.46:1.54; P= 0.58); or 
plasma iron biomarkers. Outcomes in non-pregnant women were: parasitemia (iron 42.9%, 95% CI 
38.3:47.5; control 39.2% , 95% CI 34.9:43.7, prevalence ratio 1.09, 95% CI 0.93:1.28; P=0.282); 
anemia (adjusted risk ratio 0.90, 95% CI 0.78:1.05; P= 0.17); iron deficiency (adjusted risk ratio 
0.99, 95% CI 0.77:1.28; 0.96); with no iron biomarker differences.  
Conclusions: Weekly iron supplementation did not increase malaria risk, improve iron status or 
reduce anemia in young, mostly adolescent menstruating women, nor in early pregnancy. WHO 
Guidelines for universal supplementation for young nulliparous women may need re-assessment. 
Key Words: iron supplements; malaria; adolescents; randomized trial; Burkina Faso; Non-pregnant 
and pregnant 
Trial Registration: ClinicalTrials.gov, number NCT01210040. 
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Iron deficiency debilitates millions of young women in malaria endemic areas [1]. Iron 
supplementation is recommended where anemia is prevalent, but its safety and efficacy in malarious 
areas is uncertain. Reviews of daily or intermittent iron supplementation of non-pregnant women 
include few studies from malaria endemic settings [2, 3, 4], and in iron supplementation trials in 
pregnancy, malaria outcomes are mostly not reported [5]. Two trials showed no increased malaria 
risk at delivery with daily antenatal iron supplementation but malaria exposure was very low in one 
trial [6]. The other recruited mainly multigravidae [7],
 
although in sub-Saharan Africa highest 
prevalence of P.falciparum malaria occurs during early pregnancy in primigravidae [8].
 
  World 
Health Organization (WHO) guidelines on iron supplementation are applicable to both all-age 
pregnant women and all-age menstruating women. Safety of iron-folic acid supplementation in 
young nulliparous women before, and during their first pregnancy in malaria endemic areas has not 
been evaluated [9], and primigravidae are a higher malaria risk group than multigravidae.
 
As there had been no periconceptional trials of the safety and efficacy of iron supplementation in 
young nulliparous women living in malaria endemic areas, we carried out a double blind 
randomized controlled non-inferiority trial of malaria risk prior to, and during early pregnancy, in 
nulliparous women receiving weekly iron and folic acid supplementation over a period of up to 
eighteen months. The primary outcome was malaria parasitemia at first antenatal visit. Secondary 
outcomes assessed malaria in women who remained non-pregnant, and supplement efficacy in 
reducing iron deficiency. Malaria endemicity in this study area is typical of many settings in sub-
Saharan Africa with perennial malaria transmission. 
Methods   
This periconceptional trial compared 2 cohorts supplemented with iron and folic acid versus folic 
acid alone - non-pregnant women and women who experienced pregnancy (additional details in 
Supplement 1). The study received ethical approval in Burkina Faso (Comité d’Ethique pour la 
Introduction  
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Recherche en Santé), England (Liverpool School of Tropical Medicine), and Belgium (University 
Hospital, Antwerp). All women in the trial provided written informed consent.  
The study was conducted (April 2011 - January 2014) in the Nanoro Health and Demographic 
Surveillance System area (DHSS)
 
where malaria is hyperendemic, with highest transmission 
between June and December [10]. The iron regimen used followed World Health Organization 
guidelines updated in 2016 [3, 11], and satisfied recommended nutrient intakes for non-pregnant 
women assuming 10-25% iron absorption, with potential for good compliance and reduced side 
effects compared to daily use.
 
Sample 
Eligible participants were nulliparous, non-pregnant residents in 30 villages within the DHSS area. 
Potential participants aged 15-24 years identified through the DHSS database were approached by 
female field assistants (FFA) for pre-screening, (additional details on informed consent procedures 
in Supplement 1).  We excluded women with possible or confirmed pregnancy, chronic disease (eg 
sickle cell), or illness requiring hospitalization. In this area human immunodeficiency virus 
prevalence was 1.2% among women 15–49 years and 0.76% among pregnant women [12]. At 
enrolment demographic data, history of illness, obstetric history, last menstrual period, age at 
menarche and sexual activity were recorded. A study clinician performed a general clinical 
examination, duplicate anthropometric measurements and axillary temperature. We collected 
venous blood for plasma ferritin, serum transferrin receptor (TfR), hepcidin, and C-reactive protein 
measurements (CRP). Plasma was stored at minus 80
0
 C (additional laboratory details supplement 
3). All participants received a long-lasting insecticidal net (LLIN) and single doses of albendazole 
(400mg) and praziquantel. 
Recruitment continued until the target number was reached. We anticipated 34% malaria prevalence 
in controls at first antenatal visit (ANC1), [13]. 390 women in intervention and control groups 
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would provide 90% power to detect a non-inferiority margin of 10% of malaria prevalence between 
trial arms. The number of non-pregnant nulliparous women aged 15 to 24 years necessary to reach 
the required number of pregnant women was estimated from the proportion of nulliparous women 
(0.5) of child-bearing age (0.23), aged 15-24 years (0.33), which provides 1,973 potentially eligible 
women for a population of 52,000 in the DHSS  area (Figure 1).  
Randomization and Blinding 
Participants were individually randomized to receive weekly one of identical red colored vegetable 
cellulose (hypromellose) capsules (disintegration time <30 minutes, mean 9.5 minutes), containing 
either ferrous gluconate (60 mg elemental iron, 479 mg gluconate) and folic acid 2.8 mg, or folic 
acid alone. A block allocation sequence was used with randomly determined block lengths. Four 
containers (4x20 capsules) were assigned the same randomization code and were allocated to each 
participant. The FFA kept one container per participant, obtaining a replacement as required. 
Supplements were not kept by participants.  Supplement codes, unknown to investigators and 
maintained independently by the sponsor, were revealed only after data base lock and completion of 
data analysis. Women received a card with a unique study number corresponding to the 
randomization list. Supplements were stored at 20 -25
0
C and at ambient temperature while with 
FFAs. 
Follow-up  
FFAs provided supplements during weekly home visits and ingestion was directly observed. 
Participants not located for two consecutive attempts but then re-contacted, were reported as 
temporarily absent. In cases of fever (T°≥37.5°C) or history of fever in the previous 48 hours the 
FFA performed a malaria Rapid Diagnostic Test (RDT, (Bioline SD, Malaria Antigen P.f) and if 
positive, collected a blood sample for a thick film. RDT positives were treated with artesunate-
amodiaquine following national guidelines. If no menses were reported at 5 consecutive weekly 
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visits, a urine pregnancy test was done for human chorionic gonadotropin, immediately or at the 
next weekly visit. Supplement safety and tolerability were evaluated by recording and grading 
adverse events (AE). There were two levels of recording: weekly FFA symptom using a checklist, 
and AE through passive follow-up at health facilities. Serious adverse events (SAEs), including 
deaths, were collected by active (weekly) and passive surveillance and reported according to 
available information from FFAs and health center staff. SAE classification used all available 
clinical evidence and was not bound by stringent laboratory or diagnostic criteria. If a woman died 
outside hospital, verbal autopsies were done by the DHSS team following a standardized protocol.  
At the end of the first malaria transmission season finger prick samples were taken from all non-
pregnant participants for an interim safety analysis of malaria risk (microscopy and RDT). Positive 
RDTs were treated following national guidelines (additional details in procedures, Supplement 1). 
Weekly supplements continued for 18 months, when women who remained non-pregnant were 
referred for end assessment. This included: medical history, clinical examination, anthropometry 
and axillary temperature. A venous blood sample was collected for malaria smear, hemoglobin 
(Hemocue AB), plasma ferritin, TfR, hepcidin, and CRP measurements, and for storage on filter 
paper. If febrile (≥37.5°C) or experiencing fever in the previous 48 hours, a RDT was performed 
and positives treated. Urine pregnancy tests were repeated when indicated. On trial completion 
anemic non-pregnant women (Hb <12 g/dl) received iron and folic acid tablets daily for one month, 
and if severely anemic (Hb <8g/dl) referred to hospital. 
Women becoming pregnant within the follow up period were referred to Nanoro hospital for ANC1 
with a study nurse/doctor at 13-16 weeks gestation according to the last menstrual period. The 
weekly supplement was withdrawn and hematinics provided according to national policy (60 mg 
iron, 400µg folic acid daily), although weekly follow-up continued. All women received the first 
dose of intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) if gestational 
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age was >13 weeks. Women ≤13 weeks gestation, if RDT positive, were treated with oral quinine.  
At ANC1 procedures included: routine antenatal care,  venous blood collection for RDT, malaria 
film, hemoglobin, plasma ferritin, TfR, hepcidin, zinc protoporphyrin (ZPP) and CRP 
measurements. Ultrasound was performed to confirm pregnancy, determine fetal location, number 
and viability, and gestational age. Following ANC1 women with moderate anemia (Hb 7.0-9.9 g/dl) 
received twice the recommended daily supplement during one month, and if severely anemic (Hb 
<7 g/dl), were referred to Nanoro hospital. Women followed routine ANC visits where they 
received a second IPTp dose. Routine ANC and unscheduled health center visits were recorded on 
study questionnaires by study clinicians/nurses who collected data in health centers regularly 
(additional details in Methods Supplement 1). Procedures were similar at the second study visit 
(ANC2) (33-36 weeks gestation) when women were encouraged to deliver at Nanoro Hospital or 
the nearest Health Center, where free obstetric care was provided by the study. Study nurses 
examined babies for congenital malformations within 24-48 hrs of delivery and information on 
infant survival was obtained by FFA who visited or telephoned families.  
Laboratory Measurements 
Blood samples were transported to the laboratory within 3 hours, centrifuged and aliquoted. Blood 
films were Giemsa stained and read for malaria and parasite density (additional details laboratory 
procedures, Supplement 1). Hemoglobin was measured (Sysmex automated analyser) on fresh 
whole blood, and ZPP by fluorometry (Aviv Biomedical). Plasma ferritin and TfR were measured 
using mean values from duplicate ELISA samples (Spectro Ferritin S-22 and TFC 94 TfR, RAMCO 
Inc). CRP was measured by ELISA (EU59131IBL, GmbH). Intra-assay coefficients of variation 
(CVs) were all < 10%. Plasma hepcidin was measured by competitive ELISA at an International 
Reference Laboratory (laboratory procedures, Supplement 1).  
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The primary outcome was Plasmodium parasitemia prevalence at ANC1. Pre-specified secondary 
outcomes at ANC1 were prevalence of: RDT positivity with or without fever (≥ 37.5o); clinical 
malaria (fever or history of fever in previous 48 hours with parasitemia), iron deficiency, anemia; 
adverse pregnancy outcomes, ie miscarriage, stillbirth, perinatal or neonatal death, congenital 
abnormality. In non-pregnant women at end assessment the proportion infected in the first year was 
assessed and the same pre-specified outcomes as at ANC1. Adverse events captured incidence of 
pre-specified gastrointestinal events (definitions and MedRA classification, grading and severity, 
Supplement 1 and Table S3, supplement 2). Malaria parasitemia prevalence was measured in non-
pregnant women during the first rainy season after at least six months supplementation. Adherence 
to supplementation is reported.  
Statistical analysis  
A statistical analysis plan was approved before data base lock and release of the data and analyses 
follow that plan with only minor variation. Analyses followed CONSORT guidelines for non-
inferiority trials [14]. Investigators were blinded to allocation (coded as A/B) until completion of 
the primary outcome analysis. Prevalence analyses based on data at specific time points utilized 
risk-ratio binomial models unadjusted and adjusted for season of transmission (low or high), LLIN 
use (proportion of weekly visits with reported use prior to visit date), antimalarial use in 4 weeks 
prior to visit, and whether menarcheal at baseline. Parasite density and iron biomarkers were 
analyzed using analogous ordinary regression models following logarithmic transformation. Results 
are expressed as risk-ratios (or density/biomarker level ratios) for iron treatment with 95%CI. 
Analyses of outcomes by iron deficiency utilized the same methodology, but with no menarche 
covariate. Mean hepcidin levels were compared between malaria parasitemia positive and negative 
women at ANC1 and end assessment using Mann-Whitney U-tests. Differences in proportions with 
elevated hepcidin were estimated using Fischer’s Exact test and based on the 95th percentile value 
Outcomes  
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for a healthy Dutch female population of comparable age [15]. Statistical significance was one-
sided at alpha = 0.05. 
Malaria incidence was calculated using Poisson regression models for the number of malaria 
episodes per woman with an offset of the logarithm of the period under observation (i.e. until final 
assessment, ANC1 or lost to follow up) with adjustment for LLIN use and menarche. Results are 
presented as incidence ratios for iron treatment with 95%CI. Time to first episode of malaria was 
analyzed using Cox regression models with participants censored at ANC1, final assessment or loss 
to follow up with adjustment for season (baseline hazard stratified by enrolment month to allow for  
timing of rainy season), LLIN use, menarche and iron deficiency at baseline (using adjusted ferritin 
definition). Results are expressed as hazard ratios for iron treatment with 95%CI. All analyses were 
performed using R statistical environment version 3.3 [16].
   
Results 
Of 2317 women invited for screening 1959 were randomly assigned weekly supplements (n=980, 
iron and folic acid; n=979, folic acid); 1954 (99%) comprised the intention to treat population for 
the primary outcome. 405 pregnancies (21%) occurred during follow-up, with another 73 (4%) 
early pregnancies identified at or shortly after the end assessment survey (giving 478 pregnancies in 
total) (Figure 1). Median weekly supplement adherence at ANC1 was 79% (95%CI, 65-90%, iron) 
and 80% (59-91%, folic acid) and at end assessment for non-pregnant women 83% (72-91%, iron) 
and 84% (70-92%, folic acid) (Table S1, Supplement 2). Mean plasma ferritin and sTfR/log ferritin 
ratios were not improved in women with weekly adherence ≥ 80% (Figure 2). Median weekly LLIN 
use to ANC1 was 48.8%, and to end assessment 46.7%. 
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Characteristics were similar between groups (Table 1). Adolescents (<20 years) comprised 93%. 
Women who remained non-pregnant were younger with lower body mass index. Women not 
attending were more illiterate and sexually active (Table S2, Supplement 2). Iron deficiency 
prevalence at baseline did not differ in women lost to follow-up before ANC1 (9 [2%] of 478), or 
for non-pregnant women lost to follow-up before end assessment (501, [32%] of 1549) compared to 
those followed successfully. Iron deficiency prevalence was almost two-fold higher using the 
sTfR/log ferritin ratio (22%) as biomarker than adjusted ferritin (12%) (Table 1). Elevated hepcidin 
concentration (>10.5 nmol/l) occurred in a quarter of women.  
Prevalence of P.falciparum parasitaemia in non-pregnant women during the first rainy season was 
36.4% (95% CI, 33.7-39.3, n=1167) with no difference by trial arm. 
 
 ANC1 Outcomes  
Mean gestational age was 18.5 (SD 5.5) weeks (iron and folic acid) and 18.0 (6.0) weeks (folic 
acid). Plasmodium parasitemia prevalence was 54.3%. This did not differ by trial arm (adjusted 
ratio 1.0, 0.97-1.03), nor when associated with fever. Incidence and time to the first symptomatic 
episode (fever plus parasitemia or RDT positivity), were not different between arms (Table 2). 
There was no difference between study arms in anemia or iron deficiency prevalence, or mean 
concentrations of iron biomarkers (Table 3). Median hepcidin concentration was 3.9 nmol/l (IQR 
1.7:9.0) with, and 2.9 nmol/l (0.7:7.0) without, malaria parasitemia (P= 0.005). Elevated hepcidin 
was more frequent in parasitemic (22%) compared to non-parasitemic women (11%), (P= 0.015). 
End Assessment Outcomes 
Plasmodium parasitemia prevalence was 49.0% and did not differ by trial arm (adjusted ratio 1.1, 
0.95-1.28), or if associated with fever. There was no difference between study arms in prevalence of 
Baseline 
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anemia or iron deficiency, or mean concentrations of iron biomarkers (Table 3). Median hepcidin 
concentrations in women with and without malaria parasitemia were respectively 3.4 (1.7:6.5) and 
2.9 nmol/l (1.1:6.2; P=0.011). Elevated hepcidin was similar in parasitemic (15%) compared to 
non-parasitemic women (16%), (P= 0.85). 
Adverse events 
Supplements were well tolerated but with more frequent gastro-intestinal events with iron 
supplementation (RR 1.29, 95%CI 0.93-1.79, P=0.12). Adverse events for all categories did not 
differ by trial arm (Table S3, Supplement 2). We recorded 106 adult and 81 infant SAEs with 
almost equal frequency between groups (Table 4). 6 adult deaths occurred (3 at delivery), unrelated 
to the intervention or malaria. All congenital abnormalities (1.4%) occurred in controls. There were 
17 infant/perinatal deaths, 12 to mothers who received iron.  
 
Discussion  
We found that weekly iron and folic acid supplementation for up to 18 months did not affect 
significantly prevalence of Plasmodium infection, iron deficiency or anemia, compared with folic 
acid supplements alone in either the pregnant or non-pregnant cohort. Women receiving iron 
experienced non-significantly increased gastro-intestinal effects. Asymptomatic falciparum malaria 
infection was highly prevalent despite weekly active surveillance, access to free treatments, and 
treatment of all RDT positives at the interim safety survey. 
Our trial was double blind, tablet consumption was directly observed with balanced adherence 
covering wet and dry seasons, and active surveillance identified malaria episodes. Inadequate 
supplementation is unlikely since women absent for a number of weeks were tracked and resumed 
supplements, allowing them to re-establish their iron levels. Untreated chronic asymptomatic 
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malaria may lead to tissue pathology within the gut [17] as well as elevated hepcidin concentrations 
[18], which would be expected to reduce iron absorption. In relation to a safety trial, an effect of 
iron supplementation on malaria risk becomes difficult to establish if there is limited iron 
absorption. Baseline prevalence of iron deficiency was comparable to estimates in a recent meta-
analysis for low income countries [19].
 
 In the only in vivo iron absorption study to date in young 
women, conducted in Benin, markedly reduced iron absorption with asymptomatic malaria 
infection was demonstrated, and those participants had lower median parasite densities than we 
report at ANC1 [20]. Increasing iron dosage may be inadequate to overcome this limitation.  Since 
participant diets also influence iron absorption due to high phytate content or other micronutrient 
deficiencies, effects of iron supplements may also depend on food habits and bioavailability. Better 
malaria control for adolescents could potentially both lower infection rates and improve food iron 
absorption, helping to meet growth requirements.   
In 2016, WHO revised their guidelines on iron supplementation in menstruating women and 
adolescents girls, distinguishing settings where anemia prevalence is ≥40% from >20%. It 
recommended daily use (30-60 mg elemental iron) provided for three consecutive months per year 
where prevalence is ≥40% [11], and weekly intermittent supplementation in three monthly annual 
cycles where anemia prevalence is 20-40% [3].
  
Amongst non-pregnant controls
 
in our study anemia 
prevalence was 45% at end assessment but ≤20% were iron deficient. As we saw no improved iron 
status at the higher dosage of 60 mg with up to18 months supplementation (maximum 78 doses), it 
is questionable whether daily dosage, given over three months, would be more beneficial 
(maximum 90 doses). This population has low iron deficiency prevalence despite high anemia 
prevalence. Without evidence that iron supplementation is effective in young nulliparous women 
living in malaria endemic areas, the basis for the WHO recommendation is weak and possibly 
unsafe in this group. 
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Adverse events were evenly balanced across trial arms, including miscarriages, which could result 
from early pregnancy malaria.  Gastro-intestinal adverse events were non-significantly increased in 
iron supplemented women. We have showed a two-fold increased use of antibiotics for treatment of 
gastrointestinal infections in these women, with increased use of antifungals for lower genital 
infection in the non-pregnant iron supplemented cohort [21].
 
Iron supplementation is reported to 
increase diarrhea frequency in menstruating women from non-malaria endemic areas [2]. 
Our study has some limitations. Non-attendance was greater than expected with 25% of non-
pregnant women not attending end assessment and 30% of pregnant women at ANC1, although 
contact with their families was retained to monitor AE up to birth. Attrition was equivalent between 
trial arms. Domestic labor, early sexual activity, pregnancy before marriage and migration outside 
the study area at marriage were contributory factors in failure to attend [22], and would be higher 
than in a non-adolescent population. Six percent were identified as non-menarcheal at end 
assessment, possibly related to intentional misreporting to gain free treatment [23]. Bias due to 
different premenarcheal iron requirements would be unlikely as there were equal numbers across 
study arms, but premenarcheal status reduced the conception rate. 
 
Conclusions 
In a high malaria transmission area weekly iron supplementation did not increase malaria risk, 
improve iron status or reduce anemia in young, mostly adolescent menstruating women, nor in early 
pregnancy. Iron absorption studies are required to clarify whether chronic malaria influences iron 
uptake. Baseline characteristics were typical for adolescents in low income, rural sub-Saharan 
Africa, thus our results should apply to similar malaria-endemic areas with high rates of 
asymptomatic adolescent malaria. Studies are warranted to improve malaria prevention and control 
in adolescent populations and to shape relevant interfacing iron deficiency reduction strategies. Iron 
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supplementation, as routinely given to populations such as this, is not helpful and potentially 
harmful. WHO Guidelines for universal supplementation in young nulliparous women may need to 
be re-assessed. 
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Figure 1  Trial profile 
Legend to Figure 1. Stippled arrow indicates the number of women identified in early pregnancy at 
or within two months of the end assessment survey. Secondary outcome in non-pregnant women is 
malaria parasitemia. 
Figure 2  Mean ferritin concentration and sTfR/log ferritin ratio in non-adherent and 
adherent women by trial arm 
Legend to Figure 2. Boxplots (median, interquartile and 90% ranges) for iron biomarkers in 
controls and iron-supplemented women at the three assessment points, subdivided by adherence to 
treatment.  Adherence defined as receiving ≥ 80% weekly supplement intake up to ANC1, or end 
assessment in non-pregnant women.  Broken reference lines are median baseline levels. 
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Table 1: Baseline characteristics of the intention to treat dataset 
Characteristic 
 
All 
Iron 
n=978 
All 
Control  
n=976 
Non-pregnant 
Iron 
n=766 
Non-pregnant 
Control 
n=783 
Pregnant 
Iron 
n=258 
Pregnant  
Control  
n=220 
 
Socio-demographic 
    Mean age, years (SD)  16.8(1.7) 16.8(1.8) 16.7(1.7) 16.7(1.8) 17.1(1.7)    17.1(1.7) 
Age <20 years, n (%)  914/9     78 (93.5) 910/976 (93.2) 719/766 (93.9) 737/783 (94.1) 239/258 (92.6) 199/220 (90.5) 
Mossi ethnicity, n (%) 
 
936/978(95.7) 946/975 (97.0) 730/766 (95.3) 757/782 (96.8) 250/258 (96.9) 214/220 (97.3) 
     Missing (%) 0/978 (0) 1/976 (0.1) 0/766 (0) 1/783 (0.1) 0/258 (0) 0/220 (0) 
Religion, n (%)   Catholic 414/978 (42.3) 405/975 (41.5) 317/766 (41.4) 327/782 (41.8) 118/258 (45.7) 86/219 (39.3) 
  Protestant 126/978 (12.9) 120/975 (12.3) 113/766 (14.8) 106/782 (13.6) 18/258 (7.0) 19/219 (8.7) 
     Muslim 251/978 (25.7) 250/975 (25.6) 187/766 (24.4) 203/782 (26) 75/258 (29.1) 52/219 (23.7) 
 Traditional 187/978 (19.1) 200/975 (20.5) 149/766 (19.4) 146/782 (18.7) 47/258 (18.2) 62/219 (28.3) 
 Missing (%) 0/978 (0) 1/976 (0.1) 0/766 (0) 1/783 (0.1) 0/258 (0) 1/220 (0.5) 
Education, n (%) 
    
None 595/975 (61.0) 578/974 (59.3) 447/763 (58.6) 450/781 (57.6) 176/257 (68.5) 142/220(64.5) 
 Primary 212/975 (21.7) 201/974 (20.6) 168/763 (22.0) 169/781 (21.6) 54/257 (21) 38/220 (17.3) 
  Secondary 168/975 (17.2) 195/974 (20.0) 148/763 (19.4) 162/781 (20.7) 27/257 (10.5) 40/220 (18.2) 
 
Missing (%)  3/978 (0.3) 2/976 (0.2) 3/766 (0.4) 2/783 (0.3) 1/258 (0.4) 0/220 (0) 
Literate, n (%) 
 
329/966 (34.1) 347/966 (35.9) 278/756 (36.8) 297/774 (38.4) 68/255 (26.7) 62/218 (28.4) 
 
Missing (%)  12/978 (1.2) 10/976 (1.0) 10/766 (1.3) 9/783 (1.1) 3/258 (1.2) 2/220 (0.9) 
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Occupation,  
n (%) 
a
 
    Student 300/978 (30.7) 317/976 (32.5) 255/766 (33.3) 274/783 (35) 60/258 (23.3) 51/220 (23.2) 
     Trading 32/978 (3.3) 31/976 (3.2) 24/766 (3.1) 21/783 (2.7) 10/258 (3.9) 10/220 (4.5) 
   Domestic 534/978 (54.6) 515/976 (52.8) 401/766 (52.3) 407/783 (52) 154/258 (59.7) 120/220(54.5) 
      Farmer 375/978 (38.3) 380/976 (38.9) 269/766 (35.1) 290/783 (37) 130/258 (50.4) 101/220(45.9) 
        Other 5/978 (0.5) 4/976 (0.4) 3/766 (0.4) 2/783 (0.3) 3/258 (1.2) 3/220 (1.4) 
 
Clinical 
       Menarcheal, n (%)  844/978(86.3) 829/976 (84.9) 639/766 (83.4) 645/783 (82.4) 241/258 (93.4) 203/220 (92.3) 
Sexually active, n (%)  249/978(25.5) 241/975 (24.7) 159/766 (20.8) 164/782 (21.0) 98/258 (38) 82/220 (37.3) 
Height, cm (SD)  159.0 (6.0) 159.2 (6.0) 158.6 (6.0) 159.1 (6.1) 160.0 (5.7)  159.4 (5.6) 
Weight, kg (SD)  50.2 (6.8) 50.2 (7.2) 49.6 (6.9) 49.7 (7.2) 51.6 (6.0)    51.6 (6.7) 
BMI, kg/m
 2
 (SD)  19.8 (2.1) 19.7 (2.2) 19.7 (2.1) 19.6 (2.2) 20.1 (1.8)     20.3 (2.1) 
BMI <18.5 kg/m 
2
, n (%)      257/978 (26.3) 277/976 (28.4) 222/766 (29.0) 246/783 (31.4) 46/258 (17.8) 39/220 (17.7) 
MUAC [cm] (SD)  23.7 (2.1) 23.7 (2.2) 23.6 (2.1) 23.6 (2.2) 24.1 (1.8)     24.3 (2.2) 
 
Serum Iron Biomarkers 
      Median CRP, mg/l  [IQR] 
 
0.59 
[0.23-1.47] 
0.51 
[0.20-1.35] 
0.58 
[0.23-1.43] 
0.50 
[0.18-1.29] 
0.72 
[0.27-1.64] 
       0.70 
   [0.22-1.66] 
 Missing (%)   13/978 (1.3)   13/976 (1.3)   6/766 (0.8) 12/783 (1.5) 7/258 (2.7) 2/220 (0.9) 
CRP ≥10 mg/l, n (%)  38/965 (3.9) 41/963 (4.3) 30/760 (3.9) 31/771 (4.0) 9/251 (3.6) 10/218 (4.6) 
Median ferritin µg/l  [IQR]  49.0 
[28.0-78.0] 
49.0 
[26.0-82.0] 
49.0 
[28.0-79.8] 
50.0 
[27.0-81.0] 
48.0 
[28.0-74.5] 
44.0 
[26.0-81.0] 
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 Missing (%) 12/978 (1.2) 14/976 (1.4) 8/766 (1.0) 12/783 (1.5) 4/258 (1.6) 3/220 (1.4) 
Median sTfR , mg/l  [IQR] 
 
       6.32 
[5.08-7.87] 
6.28 
[5.14-7.90] 
6.32 
[5.10-7.95] 
6.26 
[5.09-7.92] 
6.20 
[5.02-7.67] 
6.34 
[5.31-7.80] 
 Missing (%)    11/978 (1.1) 18/976 (1.8) 7/766 (0.9) 16/783 (2.0) 4/258 (1.6) 3/220 (1.4) 
Median sTfR/log10 ferritin 
ratio [IQR] 
 
3.80 
[2.88-5.13] 
3.74 
[2.88-5.36] 
3.80 
[2.88-5.13] 
3.69 
[2.86-5.25] 
3.77 
[2.88-5.13] 
3.87 
[2.94-5.61] 
 
Missing (%) 14/978 (1.4) 18/976 (1.8) 9/766 (1.2) 16/783 (2.0) 5/258 (1.9) 3/220 (1.4) 
Median hepcidin, nmol/l  
[IQR] 
 
4.80 
[2.00-10.75] 
4.30 
[1.90-10.10] 
4 .80 
[1.90-10.75] 
4.40 
[1.90-10.00] 
4.90 
[2.32-10.67] 
4.10 
[1.80-10.70] 
 
Missing (%) 11/978 (1.1) 16/976 (1.6) 7/766 (0.9) 14/783 (1.8) 4/258 (1.6) 3/220 (1.4) 
Elevated hepcidin >10.5nM/l 
n, (%) 
b 
                           Missing (%) 
251/967 (26.0) 
   11/978 (1.1) 
222/960 (23.1)  
   16/976 (1.6) 
196/759 (25.8)  
    7/766 (0.9) 
172/769 (22.4) 
   14/783 (1.8) 
65/254 (25.6) 
   4/258 (1.6) 
55/217 (25.3) 
   3/220 (1.4) 
Iron deficiency, n (%)
 c
   
(adjusted ferritin) 
105/962 (10.9) 125/961 (13) 84/758 (11.1) 100/770 (13) 25/250 (10)   26/217 (12) 
 
Missing (%) 16/978 (1.6) 15/976 (1.5) 8/766 (1.0) 13/783 (1.7) 8/258 (3.1)    3/220 (1.4) 
Iron deficiency, n (%) 
d
 
(sTfR/log/ferritin ratio >5.6)  
205/964 (21.3) 218/958 (22.8) 162/757 (21.4) 168/767 (21.9) 52/253 (20.6)  55/217 (25.3) 
 
Missing (%) 14/978 (1.4) 18/976 (1.8) 9/766 (1.2) 16/783 (2.0) 5/258 (1.9)    3/220 (1.4) 
 
a
     
Multiple answers possible for subsistence activities, ie trading, farming and domestic work 
b   Hepcidin 95% range for women aged 18-24 years from reference Dutch population was: median 2.6nM; 
2.5
th
 percentile 0.7nM; and 97.5
th
  percentile 10.5 nM [15] 
c   Ferritin < 15 µg/l if C-reactive protein (CRP) < 10 mg/l or, ferritin < 70 µg/l if CRP ≥ 10 mg/l 
d   Ratio: sTfR (µg/ml) to log10 ferritin (µg/l) >5. 
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Table 2   Malaria at first antenatal visit (ANC1) and at end assessment in non-pregnant 
nulliparae 
Endpoint Iron Control Ratio 
   P 
value 
Adjusted      
ratio Padj 
a
 
Prevalence - ANC1  
     N 163 152 
RDT positive b, n (%) 95/161 (59.0) 
[51.3:66.3] 
89/152 (58.6) 
[50.6:66.1] 
1.01  
[0.84:1.21] 
1.000 1.00 
[0.98:1.03] 
0.718 
RDT positive & fever, n 
(%) 
15/163 (9.2) 
[5.7:14.6] 
6/152 (3.9) 
[1.8:8.3] 
2.33 
[0.93:5.85] 
0.072 2.30 
[0.91:5.79] 
0.075 
Microscopy positive 
c
, n 
(%) 
86/161 (53.4)        
[45.7:61.0] 
84/152 (55.3) 
[47.3:62.9] 
0.97 
[0.79:1.18] 
0.820 1.00 
[0.97:1.03] 
0.975 
Clinical malaria d, n (%) 9/161 (5.6) 
[3.0:10.3] 
4/152 (2.6) 
[1.0:6.6] 
2.12 
[0.67:6.75] 
0.259 2.14 
[0.68:6.76] 
0.194 
Parasite density, 
parasites/cmm 
e
  
2000 
[1483:2696] 
2244 
[1674:3008] 
0.89 
[0.59:1.35] 
0.585 0.89 
[0.58:1.36] 
0.584 
Prevalence - end assessment 
a
 
     N 441 475 
   RDT positive & fever, n 
(%) 
19/432 (4.4) 
[2.8:6.8] 
30/464 (6.5) 
[4.6:9.1] 
0.68 
[0.39:1.19] 
0.188 0.69 
[0.39:1.21] 
0.193 
Microscopy positive 
c
, n 
(%)
 
 
189/441 (42.9) 
[38.3:47.5] 
186/474 (39.2) 
[34.9:43.7] 
1.09 
[0.93:1.28] 
0.282 1.10 
[0.95:1.28] 
0.180 
Clinical malaria d, n (%) 13/440 (3.0) 
[1.7:5.0] 
22/474 (4.6) 
[3.1:6.9] 
0.64 
[0.32:1.25] 
0.228 0.67 
[0.34:1.31] 
0.237 
Parasite density, 
parasites/cmm e  
302 
[248:368] 
316 
[259:386] 
0.96 
[0.72:1.27] 
0.754 0.96 
[0.73:1.27] 
0.793 
 
Incidence to end assessment in non-pregnant f 
  Person-years follow-up, 
(n)  
1114.9            
(936) 
1121.1 
(942) 
  
RDT positive, (n/N) 0.40 (445/1115) 0.40 (444/1121) 1.01 
[0.88-1.15] 
0.908 1.01 
   [0.89-1.15] 
0.867 
RDT positive & fever, 
(n/N) 
0.16 (174/1115) 0.17 (188/1121) 0.93 
[0.76-1.14] 
0.494 0.94  
[0.76-1.15] 
0.525 
Microscopy positive, (n/N) 0.25 (282/1115) 0.26 (286/1121) 0.99 
[0.84-1.17] 
0.919 1.00  
[0.85-1.18] 
0.971 
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Clinical malaria 
d
, (n/N)       0.07 (79/1115) 0.08 (87/1121) 0.91 
[0.67-1.24] 
0.558 0.92 
[0.68-1.25] 
0.582 
 
Proportion infected in first year g 
 
 
    
 
Number at risk              978               976     
Number censored at one 
year, (%)          294 (30.1) 294 (30.1) 
     
RDT positive & fever, %          13 [11:15] 14 [12:16] 
  0.89  
[0.72:1.11] 0.295 
 0.91 
[0.73:1.13] 0.386 
 
Clinical malaria d, %             6 [5:8] 7 [5:8] 
     0.92 
[0.67:1.25] 0.588 
 0.92 
[0.68:1.26] 0.617 
 
Square brackets: 95% confidence interval 
a   Prevalence adjusted for: season at visit date; bed net use up to visit date; antimalarial use in month prior to 
visit and menarcheal status at baseline. Ratio is risk ratio for iron treatment. 
b   RDT: Rapid diagnostic malaria test 
c   Parasite positive on blood smear 
d   P.falciparum blood smear positive and fever ≥ 37.5
o
C 
e   Geometric mean [95%CI] 
f    Incidence per person-year adjusted for: weekly bed net adherence and menarcheal status at baseline; ratio 
is incidence ratio 
g   Cox regression model of time to first malaria episode, adjusted for baseline iron deficiency (ferritin), bed net 
use over observation time, visit and menarcheal status at baseline and stratified by enrolment month; ratio is 
hazard ratio 
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Table 3 Anemia and iron biomarkers at ANC1 and at end assessment in non-pregnant 
nulliparae  
Endpoint n         Iron Control 
a
 
 
Effect 
b
 P   Adjusted effect 
c
 P adj 
ANC1        
Mean hemoglobin, 
g/dl 
314 10.17  
[ 9.96:10.38]  
(1 missing) 
 
10.22  
[ 9.99:10.46] 
-0.06  
[-0.36:0.25] 
0.722 -0.01  
[-0.32:0.3] 
 
0.944 
Anemia 
d
 314 112/162 (69.1)   
[61.6:75.7] 
107/152 (70.4) 
[62.7:77.1] 
0.98  
[0.85:1.14] 
0.902 0.96  
[0.83:1.10] 
 
0.524 
Severe Anemia e 314 2/162 (1.2)  
[0.3:4.4] 
4/152 (2.6) 
 [1.0:6.6] 
0.469 
[0.087:2.524] 
0.435 0.443 
[0.082:2.401] 
0.343 
Iron deficiency, 
(%) 
(adjusted ferritin)
 f
 
310 
 
11/160 (6.9) 
 [3.9:11.9] 
 
19/150 (12.7) 
[8.3:18.9] 
 
0.54  
(0.27:1.10) 
0.123 
 
0.53  
(0.26:1.09) 
0.083 
Iron deficiency, (%) 
(sTfR/log ferritin 
ratio)
 g
 
 
312 
 
18/162 
(11.1%) 
[7.1:16.9] 
 
19/150  
(12.7%) 
[8.3:18.9] 
 
 
0.88 
(0.48:1.61) 
 
0.728 
 
 
0.84 
(0.46:1.54) 
 
0.578 
 
Mean ferritin, µg/l 
 
313 
 
91 [78:107]  
(1 missing) 
87 [74:103]  
(1 missing) 
 
1.05 [0.84:1.31] 
 
0.694 
 
1.07  [0.86:1.33] 
 
0.563 
 
Mean sTfR, mg/l 
 
313 
 
6.0 [5.6:6.4]  
(1 missing) 
5.9 [5.6:6.3]  
(1 missing) 
 
1  [0.91:1.1] 
 
0.949 
 
1 [0.91:1.1] 
 
0.962 
 
Mean ZPP, 
µmol/mol Heme 
 
 
285 105 [100:111] 
(14 missing) 
106 [101:112] 
(16 missing) 
 
0.99  
[0.92:1.07] 
 
0.841 
 
0.99  
[0.92:1.07] 
 
0.857 
 
Mean hepcidin, 
nmol/l 
 
 
311 
 
3.01 [2.5:3.7]  
(3 missing) 
          
 2.86 [2.3:3.5]  
  (1 missing) 
1.05 [0.79:1.41] 
         
0.729 1.07 [0.80:1.43] 0.664 
 
Elevated hepcidin, 
>10.5nM/l h 
 
 
311 29/160 (18.1) 
[12.9:24.8] 
25/151 (16.6) 
[11.5:23.3] 
 
1.09 (0.67:1.78) 0.766 1.12 (0.69:1.83) 0.649 
 
Non-pregnant 
 
n 
 
Iron 
 
Control 
 
Effect  
b
 
 
P 
 
Adjusted effect 
 
P adj 
 
Mean hemoglobin, 
g/dl 
 
913 
 
12.02 
[11.91:12.12]  
(1 missing) 
 
11.93  
[11.82:12.04] 
 (2 missing) 
 
0.09   
[-0.07:0.24] 
 
0.261 
 
0.06   
[-0.09:0.22] 
 
0.420 
 
Anemia i 
 
913 
 
179/440 (40.7) 
 [36.2:45.3] 
 
217/473 (45.9) 
[41.4:50.4] 
 
0.89  
[0.76:1.03] 
 
0.124 
 
0.90  
[0.78:1.05] 
 
0.168 
 
Severe Anemia j 
 
 
 
913 
 
0/440 (0.0)  
[0.0:0.9] 
 
3/473 (0.6)  
[0.2:1.8] 
 
           NA 
 
0.250 
 
NA 
 
0.996 
 
Iron deficiency 
 
910 
 
38/439 (8.7)  
 
50/471 (10.6)  
 
0.82 [0.55:1.22] 
 
0.369 
 
0.82 [0.55:1.23] 
 
0.336 
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(adjusted ferritin) f [6.4:11.7] [8.1:13.7] 
 
Iron deficiency 
(sTfR/log ferritin 
ratio) 
g 
 
 
 
909 
 
89/437 (20.4)  
[16.9:24.4] 
 
97/472 (20.6)  
[17.2:24.4] 
 
0.99 [0.77:1.28] 
 
1.000 
 
0.99 [0.77:1.28] 
 
0.960 
 
Mean ferritin, µg/l 
 
912 
 
49  [46:53]  
(2 missing) 
 
51 [47:55]  
(2 missing) 
 
0.97 [0.87:1.09] 
 
0.632 
 
0.97 [0.86:1.08] 
 
0.564 
 
Mean sTfR, mg/l 
 
909 
 
6.4  [6.1:6.6]  
(4 missing) 
 
6.5 [6.2:6.7]  
(3 missing) 
 
0.98 [0.94:1.04] 
 
0.558 
 
0.98  [0.93:1.04] 
 
0.534 
 
Mean ZPP, 
µmol/mol Heme 
 
 
914 
 
101  [97:104] 
 (1 missing) 
 
  101 [98:105]   
(1 missing) 
 
0.99 [0.94:1.04] 
 
0.783 
 
 
0.99 [0.94:1.04] 
 
 
 
0.784 
 
 
Mean hepcidin, 
nmol/l 
 
909 2.85 [2.5:3.2]                
(3 missing) 
  
2.83 [2.5:3.2] 
(4 missing) 
1.01 [0.86:1.17] 
 
 
0.939 
 
1.0 [0.86:1.17] 
 
0.960 
 
Elevated hepcidin, 
>10.5nM/l 
h 
 
909 70/438 (16.0)     
[12.8:19.7] 
72/471 (15.3) 
[12.3:18.8] 
1.05 [0.77:1.41] 0.785 1.05 [0.78:1.43] 0.736 
  
  
    
 
Square brackets: 95% confidence interval 
a   N (%) for binary variables, mean [95%CI] for hemoglobin; geometric mean [95%CI] for iron biomarkers 
b   Risk ratio for binary outcomes; difference between arms for hemoglobin; ratio between arms for iron 
biomarker levels 
c   Anemia measures adjusted for: baseline menarche, season at assessment and use of antimalarials in the 
previous month. Iron measures adjusted for baseline menarche. 
d   Hemoglobin < 11g/dl 
e   Hemoglobin <8 g/dl 
f    Ferritin < 15 µg/l if C-reactive protein (CRP) < 10 mg/l or, ferritin < 70 µg/l if CRP ≥ 10 mg/l 
g   Ratio: sTfR µg/ml to log10 ferritin >5.6 
h   Hepcidin  95% reference range for women  18-24 yrs age from reference Dutch population was: median 
2.6nM; 2.5
th
 percentile 0.7nm; and 97.5
th
  percentile 10.5 nM, [15] 
i   Hemoglobin < 12g/dl 
j   Hemoglobin <7 g/d 
 
 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy257/4992610
by London School of Hygiene & Tropical Medicine user
on 15 May 2018
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 Iron Control 
 
Adult SAE  
 
N=978 
 
N=976 
                                                         
Accidental death [1] 0 1 
                                                        
Obstetric death 2 1 
                                                        
Other obstetric SAE [2] 12 7 
                                                          
 Severe malaria 27 20 
                                                                     
Other death [3] 1 1 
                                                                               
Other [4] 
                                                                
Total SAE 
12 
54 
 
22 
52 
 
Infant SAE 
 
N=231 
 
N=206 
                                                              
Miscarriage 16 11 
                                                                    
Stillbirth 13 17 
                                                                                       
Perinatal death 
1
 
 
6 0  
                                                               
Neonatal death           4 3 
                                                                                   
Infant death 
 
1      1 
          Death from congenital abnormality [5]           0                  
 
     1 
 
               Other Congenital abnormalities [6] 
2
 0 5  
                                 Other obstetric SAE [2] 2 0 
                                             Other Death [7] 
  
                                                     Total SAE 
 
1 
 
43 
0 
 
38 
 
1
 P= 0.021 (Fishers exact test) 
2
 P=0.011 for all abnormalities 
[1] One  death from drowning; [2] SOC= Pregnancy, puerperium and 
perinatal conditions, excluding deaths; [3] Neoplasms: benign, 
malignant and unspecified, (liposarcoma and thoracic pain); [4] see 
supplementary file for summary of adverse events; [5] Spina bifida; [6] 
Club foot; congenital anomaly; polydactyly (all classified as unlikely or 
definitely not treatment related). Excludes abnormalities associated 
with stillbirth/miscarriage (one microcephaly); [7] Paralytic ileus 
 
Table 4 Serious Adverse Events 
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n=27n=46
1959 Randomised
980 assigned to 
iron and folic acid 
979 assigned to 
folic acid
358 ineligible 
7 unwilling to adhere
16 not resident/planning to move 
63 pregnant/had given birth 
52 illness (see supplement 3 for listings)
220 pre-menarcheal
258 pregnant
8 L2FU/migrated
16 miscarriage
766 non-pregnant
253 L2FU/migrated
1 Died
163 ANC1 
161 Primary outcome
466 end assessment
2317 assessed
for eligibility
220 pregnant
1 L2FU/migrated
11 miscarriage
783 non-pregnant
248 L2FU/migrated
2 died
506 end assessment
152 ANC1 
152 Primary outcome
En
ro
lm
en
t
Al
lo
ca
tio
n
Fo
llo
w
-u
p
An
al
ys
is
2 protocol violations 3 protocol violations
441 menarcheal
440 Secondary outcome
475 menarcheal
474 Secondary outcome
31 never 
menarcheal
25 never 
menarcheal
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